FTC, Antitrust Org Ask 3rd Circ. To Rethink Doryx Decision

By Dani Kass (October 20, 2016, 5:00 PM EDT) -- The Federal Trade Commission and American Antitrust Institute on Wednesday each asked the Third Circuit to rethink its dismissal of Mylan Pharmaceuticals Inc.'s product-hopping suit against Warner Chilcott Ltd. over the acne medication Doryx, arguing the court changed the Sherman Act's standard of harm and misinterpreted an array of precedent. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!